Quizartinib - PDFSEARCH.IO - Document Search Engine

Quizartinib
Results: 9

#	Item
1	Day by Day Program Sunday 25th March 2:00- 6:00pm Conference Registration Desk Opens (Wandiny Room) Add to Reading List Source URL: www.sapro.com.au Language: English - Date: 2012-03-15 17:19:40 Myeloid leukemia Acute myeloid leukemia Lymphocytic leukemia CD135 Quizartinib Leukemia Myelodysplastic syndrome Myeloproliferative disease Cytarabine Oncology Medicine Acute leukemia
2	FLT3 Ligand Fms-like Tyrosine Kinase 3 Ligand human, recombinant, E. coli Cat. No. Add to Reading List Source URL: www.jenabioscience.com Language: English - Date: 2014-04-14 06:01:17 Tyrosine kinases FLT3LG CD135 Granulocyte colony-stimulating factor Receptor Quizartinib RTK class III Biology Cell biology Cell signaling
3	AMBIT BIOSCIENCES AND ASTELLAS ENTER STRATEGIC PARTNERSHIP TO RESEARCH, DEVELOP AND COMMERCIALIZE FLT3 KINASE INHIBITORS IN MULTIPLE INDICATIONS Ambit to Receive a $40 Million Upfront Cash Payment; Up to $350 Million Add to Reading List Source URL: www.astellas.com Language: English - Date: 2009-12-17 23:42:07 Cell signaling CD135 Acute myeloid leukemia Organic chemistry Quizartinib Tyrosine kinase Astellas Pharma Leukemia Lestaurtinib Oncology Acute leukemia Myeloid leukemia
4	Microsoft Word - ASH 2012 Announcement Press Release - final Add to Reading List Source URL: www.astellas.com Language: English - Date: 2012-11-06 04:03:33 Medicine Acute myeloid leukemia CD135 Leukemia Quizartinib Oncology Myeloid leukemia Acute leukemia
5	Microsoft Word - ASH 2012 Announcement Press Release (final) Add to Reading List Source URL: www.astellas.com Language: English - Date: 2012-12-10 18:40:36 Acute leukemia Myeloid leukemia Acute myeloid leukemia CD135 Morpholines Hematopoietic stem cell transplantation Leukemia Quizartinib Medicine Biology Oncology
6	AMBIT BIOSCIENCES INITIATES FIRST PHASE 2 CLINICAL TRIAL OF AC220 IN ACUTE MYELOID LEUKEMIA Potential to Support U.S. Regulatory Filing Add to Reading List Source URL: www.forwardventures.com Language: English - Date: 2011-08-15 11:58:25 Acute myeloid leukemia Cell signaling CD135 Leukemia Quizartinib Lintuzumab Lestaurtinib Oncology Acute leukemia Myeloid leukemia
7	Microsoft Word[removed]Partnership with Ambit.doc Add to Reading List Source URL: www.forwardventures.com Language: English - Date: 2011-08-15 11:58:25 Cell signaling CD135 Acute myeloid leukemia Organic chemistry Quizartinib Tyrosine kinase Astellas Pharma Leukemia Lestaurtinib Oncology Acute leukemia Myeloid leukemia
8	Microsoft Word - ASH2009 Phase I study results - FINAL.doc Add to Reading List Source URL: www.forwardventures.com Language: English - Date: 2011-08-15 11:58:25 Acute myeloid leukemia Organic chemistry Quizartinib Chemistry Leukemia Biology Tyrosine kinase Lestaurtinib Acute leukemia Myeloid leukemia CD135
9	CRENOLANIB, A NOVEL TYPE I, MUTANT-SPECIFIC INHIBITOR OF CLASS III RECEPTOR TYROSINE KINASES, PREFERENTIALLY BINDS TO PHOSPHORYLATED KINASES 1 Add to Reading List Source URL: www.gistsupport.org Language: English - Date: 2013-01-20 11:10:44 Tyrosine kinases Pyridines Pyrimidines Tyrosine kinase receptors Tyrosine kinase Tyrosine-kinase inhibitor Signal transduction Quizartinib CD135 Biology Cell signaling Organic chemistry

UPDATE